[CITATION][C] Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody …

T Dorner, MG Posch, Y Li, O Petricoul, M Cabanski… - Ann Rheum Dis, 2019
Save Cite Cited by 54 Related articles